Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have been given a consensus rating of “Moderate Buy” by the fifteen research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $209.4615.

A number of equities analysts have commented on the company. Bank of America raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price objective on the stock in a research note on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, October 8th. William Blair raised shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a report on Monday, October 6th. Robert W. Baird set a $224.00 price objective on shares of Charles River Laboratories International in a research report on Friday, January 9th. Finally, Barclays boosted their target price on shares of Charles River Laboratories International from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $223.74 on Friday. Charles River Laboratories International has a 1-year low of $91.86 and a 1-year high of $228.88. The company has a 50 day moving average of $195.91 and a 200-day moving average of $175.83. The company has a current ratio of 1.37, a quick ratio of 1.10 and a debt-to-equity ratio of 0.64. The firm has a market cap of $11.01 billion, a price-to-earnings ratio of -143.43, a PEG ratio of 6.78 and a beta of 1.61.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, topping the consensus estimate of $2.32 by $0.11. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.Charles River Laboratories International’s revenue was down .5% compared to the same quarter last year. During the same period in the previous year, the business earned $2.59 EPS. On average, equities analysts forecast that Charles River Laboratories International will post 9.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CRL. Tema Etfs LLC bought a new stake in shares of Charles River Laboratories International during the fourth quarter worth $26,000. Cromwell Holdings LLC boosted its holdings in Charles River Laboratories International by 542.9% in the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 152 shares during the last quarter. Rothschild Investment LLC increased its position in Charles River Laboratories International by 82.4% in the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after purchasing an additional 84 shares during the period. Neo Ivy Capital Management acquired a new stake in Charles River Laboratories International in the second quarter worth about $29,000. Finally, Atlantic Union Bankshares Corp bought a new stake in Charles River Laboratories International during the 3rd quarter worth about $31,000. 98.91% of the stock is currently owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.